GM2-KLH Conjugate Vaccine: Increased Immunogenicity in Melanoma Patients after Administration with Immunological Adjuvant QS-21

Cancer Research

Volumn 55, Issue 13, 1995, Pages 2783-2788

  Helling, Friedhelm ^a   Zhang, Shengle ^a   Shang, Ann ^a   Adluri, Sucharita ^a   Calves, Michele ^a   Koganty, Rao ^b   Longenecker, B Michael ^b,c,d   Yao, Tzy J ^a   Oettgen, Herbert F ^a   Livingston, Philip O ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Biomira Inc   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d CROSS CANCER INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLIOSIDE GM2; HEMOCYANIN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; IMMUNOLOGICAL ADJUVANT; VACCINE; BCG VACCINE; GANGLIOSIDE ANTIBODY; GANGLIOSIDE GD3; GANGLIOSIDE GM1; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; KEYHOLE LIMPET HEMOCYANIN; PHOSPHORYL LIPID A; QS 21; RESORCINOL; TUBERCULIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY PRODUCTION; ANTIBODY SPECIFICITY; ARTICLE; CLINICAL TRIAL; HUMAN; IMMUNOLOGY; MELANOMA; ANTIBODY RESPONSE; ANTIBODY TITER; CLINICAL ARTICLE; DOSE RESPONSE; DRUG CONJUGATION; DRUG FORMULATION; ERYTHEMA; FEVER; HEADACHE; HELPER CELL; HUMAN CELL; IMMUNOGENICITY; INTRADERMAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; PRIORITY JOURNAL; SKIN INFLAMMATION; SKIN NODULE;

ADJUVANTS, IMMUNOLOGIC; ANTIBODY FORMATION; ANTIBODY SPECIFICITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; G(M2) GANGLIOSIDE; HEMOCYANIN; HUMAN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MELANOMA; SUPPORT, U.S. GOV'T, P.H.S.; VACCINES;

EID: 0028981087     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Hakomori, S. I. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res., 45: 2405–2414, 1985.
2. Carubia, J. M., Yu, R. K., Mascala, L. J., Kirkwood, J. M., and Varga, J. M. Gangliosides on normal and neoplastic melanocytes. Biochem. Biophys. Res. Commun., 120: 500–504, 1984.
3. Hamilton, W. B., Helling, F., Uoyd, K. O., and Livingston, P. O. Ganglioside expression on human malignant melanoma assessed by quantitative immune thin layer chromatography. Int. J. Cancer., 53: 1–8, 1993.
4. Tsuchida, T., Saxton, R. E., Morton, D. L., and Irie, R. F. Gangliosides of human melanoma. J. Natl. Cancer Inst., 781: 45–54, 1987.
5. M2 antibodies in melanoma patients. Proc. Natl. Acad. Sci. USA, 84: 2911–2915, 1987.
6. M2 ganglioside. Cancer Res., 49: 7045–7050, 1989.
7. M2 in AJCC stage III melanoma patients. J. Clin. Oncol., 12: 1036–1044, 1994.
8. Livingston, P. O. The basis for ganglioside vaccines in melanoma. In: R. Metzgar and M. Mitchell (eds.), Human Tumor Antigens and Specific Tumor Therapy, Vol. 99, pp. 287–296. New York: Alan R. Liss, Inc., 1989.
9. D3 vaccines for melanoma: superior immunogenicity of KLH conjugate vaccines. Cancer Res., 54: 197–203, 1994.
10. M2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccine, 12: 1275–1280, 1994.
11. Kensil, C. R., Patel, U., Lennick, M., and Marciani, D. Separation and characterization of saponins with adjuvant activity from Quillaja saponaria molina cortex. J. Immunol., 146: 431–437, 1991.
12. ² cytotoxic T-lymphocyte responses. J. Immunol., 148: 2357–2362, 1992.
13. Shitara, K., Fujiwara, K., Igarashi, S., Ohta, S., Furuya, A., Nakamura, K., Koike, M., and Hanai, N. Immunoglobulin class switch of anti-ganglioside monoclonal antibody from IgM to IgG. J. Immunol. Methods, 169: 83–92, 1994.
14. M2 antibody with antitumor activity. Cancer Res., 54: 1511–1516, 1994.
15. Dippold, W. G., Lloyd, K. O., Li, L. T., Ikeda, H., Oettgen, H. F., and Old, L. J. Cell surface antigens of human malignant melanoma: definition of six antigenic systems with monoclonal antibodies. Proc. Natl. Acad. Sci. USA, 77: 6114–6118, 1980.
16. Hawkes, R., Niday, E., and Gordon, J. A. Dot-immune binding assay for monoclonal and other antibodies. Anal. Biochem., 119: 142–147, 1982.
17. Basten, A., and Howard, J. G. Thymus independence. In: A. J. S. Davies (ed.), Contemporary Topics in Immunobiology, Vol. 2, pp. 265. New York: Plenum Publishing Corp., 1973.
18. Mosier, D. E., and Feeney, A. The physiology of B lymphocytes capable of generating anti-polysaccharide antibody response. In: R. Bell and G. Torrigiani (eds.), Towards Better Carbohydrate Vaccines, pp. 243–262. London: Great Britain: J. Wiley & Sons, Ltd., 1987.
19. Jennings, H. J., Ashton, F. E., Gamian, A., Michon, F., and Roy, R. A chemically modified Group B meningococcal polysaccharide vaccine. In: R. Bell and G. Torrigiani (eds.), Towards Better Carbohydrate Vaccines, pp. 11–17. London: J. Wiley & Sons, Ltd., 1987.
20. Schneerson, R., Robbinson, J. B., Szu, S. C., and Yang, Y. Vaccines composed of polysaccharide-protein conjugates: current status, unanswered questions, and prospects for the future. In: R. Bell and G. Torrigiani (eds.), Towards Better Carbohydrate Vaccines, pp. 307–327. London: J. Wiley & Sons, Ltd., 1987.
21. Geysen, H. M., MacFarlan, R., Rodda, S. J., Tribbick, G., Mason, T. J., and Schoofs, P. Peptides which mimic carbohydrate antigens. In: R. Bell and G. Torrigiani (eds.), Towards Better Carbohydrate Vaccines, pp. 103–118. London: J. Wiley & Sons, Ltd., 1987.
22. Soederstroem, T. Anti-idiotypes as surrogate polysaccharide vaccines. In: R. Bell and G. Torrigiani (eds.), Towards Better Carbohydrate Vaccines, pp. 119–138. London: J. Wiley & Sons, Ltd., 1987.
23. Landsteiner, K., and Chase, M. W. Experiments on transfer of cutaneous sensitivity to simple compounds. Proc. Soc. Exp. Biol. Med., 49: 688–694, 1942.
24. Avery, O. T., and Goebel, W. F. Chemo-immunological studies on conjugated carbohydrate-proteins. J. Exp. Med., 50: 533–550, 1929.
25. Schneerson, R., Barrera, O. A., and Sutton, J. B. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide protein conjugates. J. Exp. Med., 152: 361–376, 1980.
26. Lepow, M. L. Samuelson, J. S., and Gordon, L. K. Safety and immunogenicity of Haemophilus influenzae type b polysaccharide diphtheria toxoid conjugate vaccine in infants 9 to 15 months of age. J. Pediatr., 106: 185–189, 1985.
27. Chu, C. Y., Schneerson, R., Robbins, J. B., and Rastogi, S. C Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide protein conjugates. Infect. Immun., 50: 245–256, 1983.
28. Marburg, S., Jorn, D., Tolman, L., Arison, B., McCauley, J., Kniskern, P. J., Hagopian, A., and Vella, P. P. Biomolecular chemistry of macromolecules: synthesis of bacterial polysaccharide conjugates with Neisseria meningitidis membrane protein. J. Am. Chem. Soc., 108: 5282–5287, 1985.
29. Anderson, P. Antibody response to Haemophilus influenzae type b and diphtheria toxin induced by conjugates of oligosaccharides of the type b capsule with the nontoxic CRM 197. Infect. Immun., 39: 233–238, 1983.
30. Turner, R. B., Cimino, C. O., and Sullivan, B. J. Prospective comparison of the immune response of infants to three Haemophilus influenzae type b vaccines. Pediatr. Infect. Dis. J. 10: 108–112, 1991.
31. Anderson, P., Pichichero, M. E., and Insel, R. A. Immunogens consisting of oligosaccharides from the capsule of Haemophilus influenzae type b coupled to diphtheria toxoid or CRM 197. J. Clin. Invest., 76: 52–59, 1985.
32. Weinberg, G. A., Einhorn, M. S. Lenoir, A. A., Granoff, P. D., and Granoff, D. M. Immunologic priming to capsular polysaccharide in infants immnunized with Haemophilus influenzae type b polysaccharide Neisseria meningitidis outer membrane protein conjugate vaccine. J. Pediatr., 118: 22–27, 1987.
33. D3 congeners (lactones, amide and gangliosidol) in patients with malignant melanoma. Int. J Cancer, 48: 379–385, 1991.
34. D3. Cancer Res., 50: 1403–1410, 1990.
35. D3 ganglioside in rabbits by an anti-idiotypic monoclonal antibody. J. Clin. Invest., 88: 186–192, 1991.
36. Svennerholm, L. Chromatographic separation of human brain gangliosides. J. Neurochem., 10: 613–623, 1963.